SynthesisBritish journal of cancer2022
Post-diagnosis smoking cessation and survival of patients with head and neck cancer: a systematic review and meta-analysis.
Synthesis in British journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Strategies and successes of smoking cessation methods in head and neck cancer patients: a systematic review.Cancer metastasis reviews · 2026Pooled it
- A Current Perspective of Two of the Most Aggressive Head and Neck Cancers: Pharyngeal and Laryngeal.Current oncology (Toronto, Ont.) · 2025Pooled it
- Article
- No Smoker Left Behind: Evaluation of a Population-Based, Opt-Out Smoking Cessation Program for Patients With Cancer Who Smoke.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- DNA methylation and expression of MAPRE3 affect overall survival of early-stage non-small cell lung cancer patients.Molecular oncology · 2026Article
- Survival among US adults with post-cancer-diagnosis cigarette smoking cessation.Cancer causes & control : CCC · 2026Article
- Clinical, laboratory, and medication-related factors associated with in-hospital mortality among oncology patients at a tertiary hospital in Saudi Arabia.Frontiers in pharmacology · 2026Article
- Preexisting Psychiatric Risk Factors and Any and Long-Term Opioid Use in Head and Neck Cancer.JAMA otolaryngology-- head & neck surgery · 2025Article
- Sustainment of Tobacco Use Treatment Programs Across National Cancer Institute-Designated Cancer Centers.Cancer medicine · 2025Article
- Long-term quality of life in head and neck cancer: the role of postdiagnosis smoking behavior.Journal of cancer survivorship : research and practice · 2025Article
- "Who Needs More Help?": The Predictors of Continued Smoking in Laryngeal Cancer Patients at Different Periods.Laryngoscope investigative otolaryngology · 2025Article
- Postdiagnosis Smoking Cessation and Survival Outcomes of Head and Neck Cancer Patients.Head & neck · 2025Article
- Genetic, clinical, lifestyle and sociodemographic risk factors for head and neck cancer: A UK Biobank study.PloS one · 2025Article
- Tobacco Cessation Following Laryngeal Cancer Diagnosis Predicts Response to Treatment and Laryngectomy-Free Survival.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2024Article
- Understanding the role of nerves in head and neck cancers - a review.Oncology reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cigarette smoking is the main risk factor for head and neck cancer (HNC) and many HNC patients are active smokers at diagnosis. We conducted a systematic literature review and meta-analysis to quantify the survival impact of smoking cessation at or around the time of HNC diagnosis. We searched studies published until December 31, 2021, and used random-effects meta-analysis to pool study-specific estimates into summary hazard ratio (SHR) and corresponding 95% confidence intervals (CI). Sixteen studies were published between 1983 and 2021, and over 2300 HNC patients were included. Studies were diverse in terms of design, patients, tumours and treatment characteristics, and criteria used to discriminate quitters from continued smokers. HNC patients who quit smoking at or around diagnosis had significantly better overall survival than continued smokers (SHR 0.80, 95% CI 0.70-0.91, n studies = 10). A beneficial effect of post-diagnosis smoking cessation was suggested for other survival endpoints as well, but the results were based on fewer studies (n = 5) and affected by publication bias. Cessation counselling should be offered to all smokers who start a diagnostic workup for HNC and should be considered standard multidisciplinary oncological care for HNC patients. PROSPERO registration number CRD42021245560.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.